Andrea Engel, PhD, Head of Particle Formulation Laboratory; Anne Benedikt, PhD, Head of Biopharmaceutical Laboratory; and Hans Baer, MSc, Senior Project Manager, all of Evonik, explain how their recently introduced new modular platform technology for improving the oral bioavailability of peptides may offer a feasible solution to the problem of compliance with peptide drugs. These can be highly beneficial for conditions such as diabetes, oncology and metabolic disorders but the fact they have to be delivered as injections has limited their appeal, a problem which may be solved by technology that enables it to be used as a tablet.

Link to ONdrugDelivery Magazine